For Proton-Pump Inhibitors and Fracture Risk, Not All Bones are Equal

PPI use in postmenopausal women was associated with excess risk for clinical spine, forearm, or wrist fractures but not for hip fractures.

Because proton-pump inhibitors (PPIs) suppress stomach acid secretion, calcium absorption can be affected; however, previous studies have not consistently shown excess hip fracture risk with PPI use. Investigators used data from the Women's Health Initiative to prospectively examine associations between PPI use and fracture risk in 161,806 postmenopausal women with no prior histories of hip fracture. Women were followed for a mean of 7.8 years; 2% of participants had reported PPI use at baseline.

In models adjusted for potential confounders (e.g., age, smoking, osteoporosis history, use of bisphosphonates), PPI users did not have higher risk for hip fractures than nonusers but did have significantly higher risk for clinical spine fractures (…

Reviewing Author

Wendy S. Biggs, MD

For Proton-Pump Inhibitors and Fracture Risk, Not All Bones are Equal

Topics

Reviewing Author